Eptifibatide and Cardiogenic shock - a phase IV clinical study of FDA data

Summary:

Cardiogenic shock is reported as a side effect among people who take Eptifibatide (eptifibatide), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Clopidogrel, and have Acute coronary syndrome.

The phase IV clinical study analyzes which people have Cardiogenic shock when taking Eptifibatide. It is created by eHealthMe based on reports of 697 people who have side effects when taking Eptifibatide from the FDA, and is updated regularly.

What is Eptifibatide?

Eptifibatide has active ingredients of eptifibatide. eHealthMe is studying from 697 Eptifibatide users. Check the latest studies of Eptifibatide.

What is Cardiogenic shock?

Cardiogenic shock (inadequate circulation of blood) is found to be associated with 926 drugs and 1,162 conditions by eHealthMe. Check the latest studies of Cardiogenic shock.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

697 people reported to have side effects when taking Eptifibatide.
Among them, 31 people (4.45%) have Cardiogenic shock.

Could Eptifibatide cause Cardiogenic shock?

Among these 31 people:

How long have people been on Eptifibatide when they have Cardiogenic shock? *

What is the gender of people who have Cardiogenic shock when taking Eptifibatide? *

female: 30 %
male: 70 %

What is the age of people who have Cardiogenic shock when taking Eptifibatide? *

What are other drugs people take besides Eptifibatide? *

Heparin: 10 people, 32.26%
Clopidogrel: 10 people, 32.26%
Furosemide: 9 people, 29.03%
Aspirin: 7 people, 22.58%
Metoprolol Tartrate: 6 people, 19.35%
Metoclopramide Hydrochloride: 5 people, 16.13%
Clopidogrel Bisulfate: 5 people, 16.13%
Pantoprazole Sodium: 5 people, 16.13%
Folic Acid: 4 people, 12.90%
Vecuronium Bromide: 4 people, 12.90%

What are other side effects people have besides Cardiogenic shock? *

Acute Kidney Failure: 12 people, 38.71%
Hypotension (abnormally low blood pressure): 11 people, 35.48%
Multi-Organ Failure (multisystem organ failure): 11 people, 35.48%
Anaemia (lack of blood): 11 people, 35.48%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 9 people, 29.03%
Thrombocytopenia (decrease of platelets in blood): 8 people, 25.81%
Mitral Valve Incompetence (inefficient heart valve): 7 people, 22.58%
Nosebleed (bleeding from nose): 7 people, 22.58%
Pulmonary Alveolar Haemorrhage (acute bleeding): 7 people, 22.58%
Arrhythmia Supraventricular (irregular heartbeat supraventricular origin): 7 people, 22.58%

What are the existing conditions these people have? *

Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 14 people, 45.16%
Pre-Existing Disease: 2 people, 6.45%
Percutaneous Coronary Intervention: 2 people, 6.45%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 3.23%
Heart Attack: 1 person, 3.23%
Coronary Artery Thrombosis (clot formation in coronary artery): 1 person, 3.23%
Acute Myocardial Infarction (acute heart attack): 1 person, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Eptifibatide and have Cardiogenic shock?

- Check whether Cardiogenic shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eptifibatide:

Eptifibatide (697 reports)

Browse all side effects of Eptifibatide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Cardiogenic shock:

Cardiogenic shock (926 drugs)

Browse all the conditions that are associated with Cardiogenic shock:

Cardiogenic shock (1,162 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on eptifibatide (the active ingredients of Eptifibatide) and Eptifibatide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.